Adimab's coronavirus antibody spinoff has launched with series A financing from investors including GV as it prepares for its first clinical trials.
US-based therapeutic antibody developer Adagio Therapeutics has emerged from stealth having completed a $50m series A round that included GV, a corporate venturing subsidiary of internet and technology group Alphabet.
Venture capital firms Polaris Partners and Mithril Capital co-led the round, which also featured investment and financial services group Fidelity Management and Research as well as healthcare-focused fund M28 Capital and healthcare investment firm OrbiMed.
Adagio is engineering monoclonal coronavirus antibodies focused on the types of coronaviruses present in bats,…
